Sold as Transderm Scop. Every FDA application for this active ingredient: 1 branded and 7 generic.
As of Nov 13, 2026, FDA lists 8 applications for Scopolamine (sold as Transderm Scop), first approved Dec 31, 1979, with 1 new use approved and 0 published complete response letters.
| Scopolamine | Part D | $31.4M | +0% | 251,727 |
| Transderm-Scop | Part D | $9K | -97% | 58 |
| Prospective Trial of [18F]AlF-FAPI-74 for PET Imaging of Fibroblast Activation Protein in Patients With EndometriosisEndometriosis, Deep Infiltrating Endometriosis · Universitaire Ziekenhuizen KU Leuven | Not applicable | Recruiting | Oct 15, 2026 |
| Pain After Scheduled Cesarean Delivery: Spinal Morphine With or Without Levobupivacaine Wound InfiltrationPain Management, C Section · Fundación Santa Fe de Bogota | — | Not yet recruiting | Oct 6, 2026 |
| PREterm Infants With Bronchial Obstruction - Prospective Study of Efficacy and Safety of Inhaled TiotropiumBronchial Obstruction, Premature Birth · General University Hospital, Prague | Phase 4 | Not yet recruiting | Sep 18, 2026 |
| Hyoscine Butylbromide During Transcystic Papillary Balloon Dilation for CholedocholithiasisCholedocholithiasis, Common Bile Duct Stones · Riga East Clinical University Hospital | Not applicable | Recruiting | Sep 11, 2026 |
| Multimodal Anesthesia in Robotic Laparoscopic NephrectomyAnesthesia, Anesthesia and Procedure Related Time Intervals · Fundacio Puigvert | Not applicable | Recruiting | Apr 30, 2026 |
| Imaging of Endometriosis With Total-body PET-CT (PET-Endo)Endometriosis · University of Edinburgh | — | Recruiting | Apr 13, 2026 |
| Representation of Spatiotemporal Information in Human Episodic Memory and NavigationScopolamine or Placebo, Schema to Organize Memory or no Schema · University of Arizona | Early phase 1 | Enrolling by invitation | Feb 20, 2026 |
| A Clinical Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Capsules for Preoperative Preparation in Painless Gastrointestinal Endoscopy ProceduresPainless Gastrointestinal Endoscopy · Shanghai Jiao Tong University School of Medicine | Not applicable | Not yet recruiting | Dec 9, 2025 |
| Dec 31, 1979 | Transderm ScopNDA 17874 · New dosage form | Baxter Hlthcare Corp | 30 | Marketed |
| Jan 30, 2015 | ScopolamineANDA 78830 | Difgen Pharms | 3 | Marketed |
| Jun 19, 2019 | ScopolamineANDA 203753 | Mylan Technologies | 2 | Marketed |
| Nov 24, 2020 | ScopolamineANDA 212342 | Riconpharma LLC | 3 | Marketed |
| Jan 10, 2022 | ScopolamineANDA 208769 | Actavis Labs Ut Inc | 0 | Marketed |
| May 6, 2024 | ScopolamineANDA 215329 | Rhodes Pharms | 0 | Marketed |
| Aug 29, 2024 | ScopolamineANDA 217893 | Zydus Pharms | 1 | Marketed |
| Jun 9, 2025 | ScopolamineANDA 218384 | Amneal | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Baxter Hlthcare Corp
Zydus Pharms